HR Execs on the Move


 
Abzena is a life science group with headquarters in the UK, and chemistry and manufacturing sites in the US. Abzena`s complimentary services and technologies in chemistry, biology and manufacturing, are applied to the selection, development and manufacture of better biopharmaceuticals. Abzena works with most of the top 20 biopharmaceutical companies and academic groups around the world, and has enabled many of them to progress products (ABZENA inside), through to clinical development. Abzena`s teams at the Babraham Research Campus, Cambridge, UK, in San Diego, CA and Bristol, PA in the US are focused on developing better treatments for ...
  • Number of Employees: 250-1000
  • Annual Revenue: $100-250 Million
  • www.abzena.com
  • 8810 Rehco Road
    San Diego, CA USA 92121
  • Phone: +44 1223 903498

Executives

Name Title Contact Details
Kimberly Burrell
Senior Vice President of Global Marketing Profile
Gavin Murdoch
Vice President Commercial Strategy Profile
Lee Wishnov
Sr. Director of Human Resources Profile
Thomas Castellano
Chief Financial Officer Profile
Patrice Dudley Aviles
Chief Human Resources Officer Profile

Similar Companies

The DNA Repair Company

The DNA Repair Company is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Shionogi USA

Shionogi USA, Inc. is a Florham Park, NJ-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Helm Pharmaceuticals

Helm Pharmaceuticals is a Chappaqua, NY-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

The Degge Group

The Degge Group is a Arlington, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Delfi Diagnostics

Delfi is developing a new class of liquid biopsy tests for early detection based on altered genome-wide fragmentation profiles, also known as "fragmentomes," representing aberrant packaging of DNA in cancer cells. By applying advanced machine learning algorithms, these fragment patterns are detectable at a very low sequencing cost. Delfi is using this technology to develop highly sensitive and specific cancer detection assays intended for wide and cost-effective distribution and adoption.